Re: Radicava with ALS score of 2 or less
Hi Maria,
Regarding Radicava (Edaravone), start by looking at the links Nikki sent you in the other thread. Also read the thread in this forum on people’s experiences receiving Radicava.
Here is a summary of what I think are some of the important points with this drug:
— the drug has been available less than a year
— the initial studies were done in Japan. —The first study looked at a larger group of patients with ALS of varying duration and functional status and failed to show a benefit
— A second study looked at patients with ALS of 2 years or less and good functional status (especially with good respiratory status). That group showed a slower rate of disease progression than patients getting placebo.
— Radicava doesn’t make ALS better. It just slows down the rate of decline in some people— mostly the people with early disease and good functional status.
— the drug is very, very expensive
— the drug is given intravenously for 14 days in a row the first month, and then 10 days out of 14 for each month after that.
— Most people get an intravenous port placed in their chest
— not many side effects
— it may be hard to get this drug in some countries
I hope that answers some of your questions. Best of luck.